Rationale and design of the screening of pulmonary hypertension in systemic lupus erythematosus (SOPHIE) study by Wong, KL et al.
Title Rationale and design of the screening of pulmonaryhypertension in systemic lupus erythematosus (SOPHIE) study
Author(s)
HUANG, D; Cheng, Y; Chan, PHM; Hai, SHJJ; Yiu, KH; Tse, HF;
Wong, KL; Fan, K; Li, YW; Ng, WL; Yim, CW; Wong, CJ; Tam, LS;
Wong, PCH; Wong, CY; Ho, CH; Leung, AMH; Mok, CC; Lam, H;
Lau, CS; Cheung, TT; Ho, CTK; Law, WY; Chan, EW; Yin, LX;
Yue, WS; Mok, TM; Evora, MA; Siu, DCW
Citation ERJ Open Research, 2018, v. 4, p. 00135-2017
Issued Date 2018
URL http://hdl.handle.net/10722/253559
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Rationale and design of the screening of
pulmonary hypertension in systemic
lupus erythematosus (SOPHIE) study
Duo Huang1, Yang-Yang Cheng1, Pak-Hei Chan1, Jojo Hai1, Kai-Hang Yiu1,
Hung-Fat Tse1, Ka-Lam Wong2, Katherine Fan2, Ying Wah Li 3,
Woon-Leung Ng4, Cheuk-Wan Yim5, Cheuk-hon John Wong6, Lai-Shan Tam7,
Priscilla C.H. Wong7, Chi-Yuen Wong8, Chup-Hei Ho9, Alexander M.H. Leung9,
Chi-Chiu Mok10, Ho Lam11, Chak-Sing Lau12, Tommy Cheung12, Carmen Ho12,
Sharon W.Y. Law13, Esther W. Chan 13, Li-Xue Yin14, Wen-Sheng Yue15,
Toi Meng Mok16, Mario Alberto Evora16 and Chung-Wah Siu1
ABSTRACT Current guideline-recommended screening for pulmonary hypertension in patients with
systemic sclerosis has not been evaluated in systemic lupus erythematosus (SLE), which is
disproportionately prevalent in Asians.
This multicentre, cross-sectional screening study aims to study the prevalence of pulmonary
hypertension among SLE patients using these guidelines, and identify independent predictors and develop
a prediction model for pulmonary hypertension in SLE patients.
SLE patients from participating centres will undergo an echocardiography- and biomarker-based
pulmonary hypertension screening procedure as in the DETECT study. Standard right heart
catheterisation will be provided to patients with intermediate or high echocardiographic probability of
pulmonary hypertension. Those with low echocardiographic probability will rescreen within 1 year. The
primary measure will be the diagnosis and types of pulmonary hypertension and prevalence of pulmonary
hypertension in SLE patients. The secondary measures will be the predictors and prediction models for
pulmonary hypertension in SLE patients. The estimated sample size is approximately 895 participants.
The results of the SOPHIE study will be an important contribution to the literature of SLE-related
pulmonary hypertension and may be immediately translatable to real clinical practice. Ultimately, this
study will provide the necessary evidence for establishing universal guidelines for screening of pulmonary
hypertension in SLE patients.
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Introduction
Pulmonary arterial hypertension is a devastating and often life-threatening complication of connective
tissue diseases. In the registry to evaluate early and long-term pulmonary arterial hypertension disease
management (REVEAL), a 55-centre longitudinal US-based registry involving 3515 patients with
pulmonary arterial hypertension, connective tissue disease accounted for >50% of all patients with
pulmonary arterial hypertension, in which systemic sclerosis comprised the largest connective tissue
disease-related pulmonary arterial hypertension [1]. Despite advances in pharmacological therapy, the
majority of patients with the condition remain asymptomatic and the diagnosis is often made late in the
course of the disease when most small pulmonary arteries have been obliterated, rendering this therapy
ineffective. For instance, 79% of new cases of systemic sclerosis-related pulmonary arterial hypertension in
the French Pulmonary Arterial Hypertension Network between 2006 and 2009 were in New York Heart
Association functional class III or IV at the time of diagnosis [2]. As such, early detection of pulmonary
arterial hypertension in high-risk connective tissue disease patients is recognised as a crucial next step to
further improve the outcomes of this devastating condition. In the detection of pulmonary arterial
hypertension in systemic sclerosis (DETECT) study in patients with systemic sclerosis [3], an
echocardiography- and biomarker-based strategy has been shown to be a sensitive and noninvasive tool to
identify pulmonary arterial hypertension with minimal false negatives. To date, the European Society of
Cardiology (ESC)/European Respiratory Society (ERS) guidelines for the diagnosis and treatment of
pulmonary hypertension recommend routine annual screening tests using resting transthoracic
echocardiography, diffusion capacity of the lung for carbon monoxide and biomarkers to detect
pulmonary arterial hypertension in asymptomatic systemic sclerosis patients [4].
In a stark contrast to Caucasian countries, SLE is the more common connective tissue disease than systemic
sclerosis in the Asia-Pacific region, with a reported incidence ranging from 0.9 to 3.1 per 100000 population
per year and a prevalence ranging from 4.3 to 45.3 per 100000 population, 2–3-fold more prevalent than in
the Caucasian population [5]. In a recent study involving a consecutive cohort of 190 patients with
connective tissue disease-related pulmonary arterial hypertension between 2006 and 2014 from China, in
contrast to the US-based REVEAL registry [1], SLE instead of systemic sclerosis comprised the largest
proportion of all connective tissue disease-related pulmonary arterial hypertension (58.4%), whereas systemic
sclerosis accounted for only 26.3% [6]. Unlike systemic sclerosis, international guidelines [4] and expert
consensus [7] do not recommend routine screening for pulmonary arterial hypertension in asymptomatic
SLE patients. One of the major reasons is the wide variation of the reported prevalence of pulmonary
arterial hypertension in SLE patients [8–23], ranging from 0.5% to 17.5% (table 1). This is at least partly
related to the heterogeneity in study design, definition of pulmonary hypertension, and, more importantly,
the infrequent use of standard right heart catheterisation to confirm and classify pulmonary hypertension as
in the DETECT study for systemic sclerosis. This may adversely affect the positive and negative predictive
values, and thereby the cost-effectiveness of the screening procedure [3]. Equally importantly, these studies
are also limited by the small sample size, typically less than 1000 participants [24–28], hampering the
prospect to identify predictors of pulmonary arterial hypertension [29] as well as to develop a prediction
model for the occurrence of pulmonary arterial hypertension. Furthermore, as only a few studies originated
from Asian SLE cohorts [9, 13, 18, 22], the generalisability to Asian SLE patients remains questionable.
The screening of pulmonary hypertension in SLE (SOPHIE) study is a cross-sectional screening study to
apply the current ESC/ERS guideline-recommended pulmonary arterial hypertension screening algorithm
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for systemic sclerosis to a large cohort of unselected Chinese SLE patients in Hong Kong [4]. The study
objectives include: 1) to describe the prevalence of pulmonary arterial hypertension among Chinese SLE
patients using the current ESC/ERS guideline-recommended screening algorithm for pulmonary arterial
hypertension in systemic sclerosis, 2) to identify independent predictors of pulmonary arterial
hypertension in Chinese SLE patients and 3) to develop a prediction model for pulmonary arterial
hypertension in Chinese SLE patients.
Material and methods
Participating centres
The study will be conducted on a multicentre basis in Asia. Participating centres must have a specialised
rheumatology clinic with more than 200 SLE patients actively followed up, in which >80% patients
consent to participate in the study. We expect seven to 10 centres from the Asia-Pacific region.
Patients and patient recruitment strategy
Chinese patients fulfilling the revised American College of Rheumatology (ACR) classification criteria for
SLE [30] or 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE
[31] from the lupus clinics in participating hospitals are eligible for the study. In addition, patients must
be aged ⩾18 years at enrolment and voluntarily agree to participate by providing written informed
consent. Patients with SLE followed up in the participating hospitals will be identified via the
computerised database of the clinical management system and will be contacted by a research nurse from
the participating hospitals. The design and objectives of the study will then be discussed with the research
nurse. An invitation information leaflet detailing the study will be provided to the candidate patients at the
same time. Patients who fail or refuse to provide written informed consent will be excluded. Table 2
summarises the five items included in the study screening procedure. According to the ESC/ERS
guidelines [4], standard right heart catheterisation will be provided to patients with intermediate or high
echocardiographic probability of pulmonary hypertension. For those with low echocardiographic
TABLE 1 Reported prevalence of pulmonary hypertension in systemic lupus erythematosus
First author [ref.] Year Methodology Patients n Prevalence %
PEREZ [15] 1981 Right heart catheterisation 43 9.3
QUISMORIO [17] 1984 Right heart catheterisation 400 0.5
SIMONSON [19] 1989 Echocardiographically derived PAP >30 mmHg 36 14.0
ASHERSON [8] 1990 Right heart catheterisation 500 5.0
WINSLOW [21] 1995 Echocardiographically derived PAP >30 mmHg 36 14.0
LI [13] 1999 Echocardiography and autopsy 419 4.0
SHEN [18] 1999 Echocardiographically derived PAP >30 mmHg 84 11.0
PAN [14] 2000 Echocardiographically derived PAP >30 mmHg 786 5.8
TANAKA [20] 2002 Echocardiographically derived PAP >40 mmHg 194 6.2
GONZALEZ-LOPEZ [23] 2004 Echocardiographically derived PAP >30 mmHg 204 16.0
JOHNSON [12] 2004 Echocardiographically derived PAP >40 mmHg 129 14.0
CHUNG [9] 2006 Echocardiographically derived PAP >45 mmHg 181 11.0
FARZANEH-FAR [10] 2006 Echocardiographically derived PAP >35 mmHg 200 17.5
PRABU [16] 2009 Echocardiographically derived PAP >30 mmHg 283 4.2
LI [22] 2014 Echocardiographically derived PAP >40 mmHg 1934 3.8
GHOFRANIHA [11] 2017 Echocardiographically derived PAP >40 mmHg 50 10.0
PAP: pulmonary arterial pressure.
TABLE 2 Screening procedure for pulmonary hypertension
1) Demographic data, data pertinent to systemic lupus erythematosus and other cardiovascular risk
factors/conditions
2) Standard 12-lead ECG
3) Nail-fold video capillaroscopy
4) Plasma concentration brain natriuretic peptide and other biomarkers
5) 6-min walk distance
6) Echocardiography
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probability of pulmonary hypertension, the screening procedure will be repeated within 1 year to ensure
the true negativity (figure 1).
Study design
SOPHIE is a multicentre, cross-sectional screening study. The study is registered with ClinicalTrials.gov
(registration number NCT03446339). The study protocol has been approved by the Institutional Review
Board of The University of Hong Kong and Hong Kong West Cluster, Hospital Authority, Hong Kong.
Approvals from other participating hospitals will be obtained subsequently. Written consent will be
obtained from each participant, and the study will be performed in accordance with the ethical standards
laid down in the Declaration of Helsinki and its later amendments.
Demographic data collection
Demographic data and ACR SLE criteria, date of SLE diagnosis, immunological abnormalities, SLEDAI-2K
(SLE disease activity index-2K) score (supplementary appendix S1) and SLICC/ACR damage index
(supplementary appendix S2) will be collected. Past and present treatment modalities for SLE together
with the corresponding duration will also be recorded. In addition, cardiovascular risk factors, history of
other cardiovascular disease and investigation results within 3 months, including serum urea, serum
creatinine, estimated glomerular filtration rate and diffusion capacity of the lung for carbon monoxide, will
also be recorded. Table 3 summarises the demographic data and data pertinent to SLE and other
cardiovascular risk factors and/or conditions to be collected.
Nail-fold video capillaroscopy
Prior studies have shown that microvascular abnormalities detected by nail-fold video capillaroscopy
appear to be related to the disease severity and the presence of specific autoantibodies in the serum of SLE
patients [32]. However, little is known about the relationship between these abnormalities and pulmonary
vasculature damage. The nail-fold of the second, third, fourth and fifth fingers of both hands in each
patient will be examined using an optical probe video capillaroscope equipped with a ×200 magnification
contact lens and connected to image analysis software (Videocap; DS MediGroup, Milan, Italy). Patients
will be inside the examination room for a minimum of 15 min before the nail-fold examination, where the
temperature is kept at 21–25°C. The pattern of microangiopathy will then be classified as “early”, “active”
and “late”, as previously reported in systemic sclerosis [33].
Echocardiographic examination
Detailed quantitative transthoracic echocardiography examination including two-dimensional, M-mode
and Doppler flow studies will be performed in all patients. Standard two-dimensional and M-mode
measurements will be performed according to the recommendations of the American Society of
Echocardiography [34]. Valvular regurgitation will be classified as “mild”, “moderate” or “severe” using a
FIGURE 1 Study flow. SLE: systemic
lupus erythematosus; BNP: brain
natriuretic peptide; V/Q: ventilation/
perfusion.
SLE patients
1) Demographic data 
2) 12-lead ECG
3) Nail-fold video capillaroscopy 
4) Plasma BNP and other biomarkers
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semiquantitative method [35]. A standard Doppler echocardiographic method will be used to estimate
cardiac output [36]. For the calculation of cardiac output, an average of five consecutive ventricular
systoles during sinus rhythm or an average of 13 beats in the case of atrial fibrillation will be obtained
[37]. Simultaneous blood pressure measurements will be made with a calibrated noninvasive
semiautomatic device (Dinamap 1846XT; Critikon, Tampa, FL, USA) during the determination of cardiac
output. Total vascular resistance (TVR) will be calculated as:
TVR dynscm5 ¼ 80Mean arterial blood pressure mmHg
Cardiac output Lmin1
For the right heart, specific transthoracic echocardiographic measurements will be performed based on the
guidelines for the echocardiographic assessment of the right heart in adults from the American Society of
Echocardiography, which is endorsed by the European Association of Echocardiography [38]. Specifically,
right atrial dimensions will be assessed using right atrial area (normal <18 cm2), right atrial length
(normal <53 mm) and right atrial diameter (normal <44 mm). Right ventricular dimensions will be
estimated at the base (normal <42 mm) and at the mid level (normal <35 mm) as well as the longitudinal
dimension (normal <86 mm) at end-diastole from a right ventricular-focused apical four-chamber view
with images demonstrating the maximum diameter of the right ventricle without foreshortening (figure 2a).
Additional right ventricular dimensions at the right ventricular outflow tract (RVOT) will be measured:
1) proximal RVOT diameter at the left parasternal long axis view for the proximal portion of the RVOT
(normal <33 mm) and 2) distal RVOT diameter at the left parasternal short axis view demonstrating
RVOT at the level of the pulmonic valve (normal <27 mm). Right ventricular wall thickness will be
measured at the left parasternal view in diastole (normal <5 mm). In addition, right ventricular systolic
function will be assessed using tricuspid annular plane systolic excursion and right ventricular fractional
area change (FAC) (figure 2b and c) [1]:
Right ventricular FAC %¼100Right ventricular end-diastolic area Right ventricular end-systolic area
Right ventricular end-diastolic area
Right ventricular systolic pressure will be determined using continuous-wave Doppler echocardiography.
Additional parameters for estimation of the right atrium include 1) inferior vena cava diameter and
2) Caval index, which measures the respiratory collapse of the inferior vena cava [39, 40]. Additional
echocardiographic signs of pulmonary hypertension include 1) dilated right ventricle with right ventricular
to left ventricular basal diameter >1.0, 2) flattening of the interventricular septum, 3) dilated pulmonary
artery, 4) dilated inferior vena cava and 5) dilated right atrium. In addition, the presence and the degree of




SLE Age of diagnosis and disease duration
Raynaud’s phenomenon
Telangiectasia
System involvements: pleuritis, pericarditis and interstitial lung disease
Immunological abnormalities: anti-RNP antibodies, anti-SSA/Ro antibodies and
anticardiolipin antibodies
SLEDAI-2K (supplementary appendix S1)
Nail-fold video capillaroscopy: microangiopathy (“early”, “active” and “late”)
Present and past treatment modalities and the corresponding duration for SLE
Cardiovascular
data
Risk factors Hypertension, diabetes mellitus and hyperlipidaemia
Diseases Coronary artery disease, peripheral artery disease, stroke, myocardial infarction,
heart failure, atrial fibrillation and other conduction abnormalities
Renal function Serum urea, serum creatinine and estimated glomerular filtration rate
Lung function test Diffusion capacity of the lung for carbon monoxide
SLE: systemic lupus erythematosus; RNP: ribonucleoprotein; SSA: Sjögren’s syndrome A; SLEDAI-2K: SLE
disease activity index-2K score.
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pericardial effusion as well as the possible aetiological causes will be recorded. The echocardiographic
probability of pulmonary hypertension will be classified into “low”, “intermediate” and “high” according to
the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension (table 4) [4].
Right heart catheterisation
According to the ESC/ERS guidelines [4], standard right heart catheterisation will be provided to patients
with intermediate or high echocardiographic probability of pulmonary hypertension. Pulmonary arterial
hypertension is defined as mean pulmonary arterial pressure >25 mmHg with a pulmonary capillary
wedge pressure ⩽15 mmHg and pulmonary vascular resistance >3 Wood units obtained at right heart
catheterisation. Pulmonary hypertension will be further classified into five groups according to
haemodynamic findings obtained from the right heart catheterisation, clinical presentation and other
pathological findings accordingly [4].
Study measures
The primary measure will be the diagnosis and the types of pulmonary hypertension in Chinese SLE
patients. The prevalence of pulmonary arterial hypertension among Chinese SLE patients will be
determined. The secondary measures will be the predictors for the occurrence of pulmonary arterial
hypertension in Chinese SLE patients.
Sample size calculation
The minimal sample size for the SOPHIE study is estimated based on 1) the prevalence of pulmonary














Right atrial area: <18 cm2
a) b) c)
FIGURE 2 Echocardiography view. a) Apical four-chamber view showing right atrial and ventricular
dimensions. b, c) Right ventricular fractional area change (see main text for calculation): b) right ventricular
end-diastolic area (yellow) and c) right ventricular end-systolic area (red).
TABLE 4 Echocardiographic probability of pulmonary hypertension according to European













31 2.8 or not
measurable
No Low
31 2.8 or not
measurable
Yes Intermediate
32–46 2.9–3.4 No Intermediate
32–46 2.9–3.4 Yes High
>46 >3.4 Not required High
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algorithm from the DETECT study of 97% and 35%, respectively, 3) the precision of estimates of
sensitivity or specificity, and 4) type I error of 0.05 [41]. A minimum of 895 SLE patients will be required
for a sensitivity of 97% and a precision estimate of 0.05 for the SOPHIE study. Approximately 2000 SLE
patients will be recruited so that the sample size will be adequate.
Statistical analysis
Continuous variables will be expressed as mean with standard deviation. Statistical comparisons between
SLE patients with and without pulmonary arterial hypertension will be performed using the t-test or
Fisher’s exact test, as appropriate. The hazard ratio and 95% confidence interval of each variable to predict
pulmonary arterial hypertension will be determined using a multivariate Cox regression model with a
p-value <0.1 for inclusion. The prognostic performance of models in predicting pulmonary arterial
hypertension will be assessed using c-statistics. The c-statistic for the receiver operating characteristic curve
will be calculated using Analyse-it for Excel (Analyse-it, Leeds, UK) with the Delong–Delong comparison
for the c-statistic. A p-value <0.05 will be considered as significant. Calculations will be performed using
SPSS version 12.0 (IBM, Armonk, NY, USA) and MedCalc version 13.1.2 (MedCalc, Ostend, Belgium).
Discussion
Despite advances in therapeutic options, the prognosis of pulmonary arterial hypertension remains poor.
Early diagnosis of pulmonary arterial hypertension is associated with improved long-term survival and
therefore early detection of pulmonary arterial hypertension in high-risk patients has been identified as a
crucial next step to further improve the outcomes of this devastating condition. It is clear from the
DETECT study in patients with systemic sclerosis that a multimodal approach using echocardiography and
biomarkers is a sensitive, noninvasive tool to identify pulmonary arterial hypertension with minimal false
negatives [3]. The approach is recommended for screening of pulmonary arterial hypertension in patients
with systemic sclerosis [4]. Uncertainties exist about the extension of this strategy to other connective
tissue diseases, which has not been systemically evaluated.
In the Asia-Pacific region, SLE is known to be more prevalent and severe in non-Caucasian populations;
however, the body of evidence regarding Asian SLE has largely been extrapolated from studies on Asian
minorities residing in the West. Indeed, the burden of connective tissue disease-related pulmonary arterial
hypertension originated from SLE instead of systemic sclerosis. In fact, SLE comprises >50% of all
connective tissue disease-related pulmonary arterial hypertension (58.4%) in Asians. Experience obtained
from pulmonary arterial hypertension screening strategies in systemic sclerosis may serve as a model for
Asian SLE patients. Extension of the screening strategy for pulmonary arterial hypertension in systemic
sclerosis with known sensitivity and specificity [3] to SLE patients can harmonise and unify early detection
and diagnostic strategies across different connective tissue diseases. The SOPHIE study will explore the
application of the screening strategy for pulmonary arterial hypertension currently recommended for
systemic sclerosis to SLE patients. As such, the SOPHIE study aims for a large sample size of at least 2000
SLE patients to ensure adequate power to document the true prevalence of pulmonary arterial
hypertension. In addition, the central requirement of >80% recruitment of SLE patients is to ensure a
relatively unselective study population to avoid selection or survival bias. An additional advantage of
having a large study population is to allow identification of individual predictors of pulmonary arterial
hypertension that can be used to develop prediction models, which can facilitate prioritisation of SLE
patients for screening procedures. One of the major challenges of the SOPHIE study is that unlike the
DETECT study for patients with systemic sclerosis mandating right heart catheterisation for all screened
patients, in the SOPHIE study, right heart catheterisation will be performed only for patients with
intermediate or high echocardiographic probability of pulmonary hypertension according to ESC/ERS
guidelines [4]. Thereby, the false-negative rate based on the low echocardiographic probability of
pulmonary hypertension may potentially underestimate the “true” false negativities as documented with
right heart catheterisation.
In summary, we propose a cross-sectional screening study to apply the current guideline-recommended
pulmonary arterial hypertension screening algorithm for systemic sclerosis to a large cohort of unselected
Chinese SLE patients. The results of the SOPHIE study will provide the prevalence of pulmonary
hypertension and the types of pulmonary hypertension in Chinese SLE patients. The study will also
identify individual predictors for the occurrence of pulmonary arterial hypertension in Chinese SLE
patients, followed by prediction model development. The SOPHIE study will be an important contribution
to the SLE pulmonary hypertension literature as one of the first systemic screening studies using the
established screening protocol in systemic sclerosis patients. Ultimately, this study will provide the
necessary evidence for establishing universal guidelines for the screening of pulmonary hypertension in
SLE patients.
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